The toxicity and efficacy of donor lymphocyte infusions given after reduced-intensity conditioning allogeneic stem cell transplantation

Blood

Volumn 100, Issue 9, 2002, Pages 3108-3114

  Marks, David I ^a,b   Lush, Richard ^a   Cavenagh, Jamie ^a   Milligan, Donald W ^a   Schey, Steven ^a   Parker, Anne ^a   Clark, Fiona J ^a   Hunt, Linda ^a   Yin, John ^a   Fuller, Steven ^a   Vandenberghe, Elisabeth ^a   Marsh, Judith ^a   Littlewood, Timothy ^a   Smith, Graeme M ^a   Culligan, Dominic ^a   Hunter, Ann ^a   Chopra, Rajesh ^a   Davies, Andrew ^a   Towlson, Keiren ^a   Williams, Catherine D ^a  

^a NOTTINGHAM CITY HOSPITAL   (United Kingdom)

^b BRISTOL ROYAL HOSPITAL FOR CHILDREN   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; BUSULFAN; CARMUSTINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTARABINE; ETOPOSIDE; FLUDARABINE; MELPHALAN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CHIMERA; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DISEASE COURSE; DONOR; FEMALE; GRAFT VERSUS HOST REACTION; HODGKIN DISEASE; HUMAN; HYPOPLASIA; LEUKEMIA; LYMPHOCYTE TRANSFUSION; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; MYELOMA; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROGNOSIS; SIBLING; STEM CELL TRANSPLANTATION; SURVIVAL TIME; UNITED KINGDOM;

EID: 0036839595     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-02-0506     Document Type: Article

References (18)

1. Kottaridis PD, Milligan DW, Chopra R, et al. In vivo Campath 1H prevents graft versus host disease following non myeloablative stem cell transplantation. Blood. 2000;96:2419-2425.
2. Giralt S, Thall PF, Khouri I, et al. Melphalan and purine analog-containing preparative regimens: Reduced intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood. 2001;97:631-637.
3. McSweeney PA, Niederwieser D, Shizuru JA, et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: Replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood. 2001;97:3390-3400.
4. Childs R, Chernoff A, Contentin N, et al. Regression of metastatic renal cell carcinoma after non-myeloablative allogeneic peripheral stem cell transplantation. N Engl J Med. 2000;343:750-758.
5. Lush RJ, Haynes AP, Byrne JL,et al. Allogeneic stem-cell transplantation for lymphoproliferative disorders using BEAM-Campath (+/-fludarabine) conditioning combined with post-transplant donor-lymphocyte infusion. Cytotherapy. 2001;3:203-210.
6. Craddock C, Bardy P, Kreiter S, et al. Engraftment of T cell depleted allogeneic stem cells using a reduced intensity conditioning regimen. Br J Haematol. 2000;111:797-800.
7. Mattson J, Uzunel M, Brune M, et al. Mixed chimaerism is common at the time of acute graft-versus-host disease and disease response in patients receiving non-myeloablative conditioning and allogeneic stem cell transplantation. Br J Haematol. 2001;115:935-944.
8. Dazzi F, Szydlo RM, Cross NCP, et al. Durability of responses following donor lymphocyte infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia. Blood. 2000;96:2712-2716.
9. Mackinnon S, Papadopoulos EB, Carabasi MH, et al. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukaemia after bone marrow transplantation: Separation of graft versus leukaemia responses from graft versus host disease. Blood. 1995;86:1261-1268.
10. Porter DL, Roth MS, McGarigle C, et al. Induction of graft versus host disease as immunotherapy for relapsed chronic myeloid leukaemia. N Engl J Med. 1994;330:100-106.
11. Kolb HJ, Schattenberg A, Goldman JM, et al. Graft versus leukemia effect of donor lymphocyte infusions in marrow grafted patients. Blood. 1995;86:2041-2050.
12. Collins RH, Shpilberg O, Drobyski WR, et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol. 1997;15:433-444.
13. Lokhorst HM, Schattenberg A, Cornelissen JJ, et al. Donor leukocyte infusions are effective in relapsed multiple myeloma after allogeneic bone marrow transplantation. Blood. 1997;90:4206-4211.
14. Alyea EP, Soiffer RJ, Canning C, et al. Toxicity and efficacy of defined doses of CD4(+) donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant. Blood. 1998;91:3671-3680.
15. Przepiorka D, Weisdorf D, Martin P, et al. 1994 consensus conference on acute GVHD grading. Bone Marrow Transplant. 1995;15:825-828.
16. Cwynarski K, Goulding R, Pocock C, et al. Immune haemolytic anaemia following T cell-depleted allogeneic bone marrow transplantation for chronic myeloid leukaemia: Association with leukaemic relapse and treatment with donor lymphocyte infusions. Bone Marrow Transplant. 2001;28:581-586.
17. Peggs K, Kottaridis P, Morris E, et al. Escalating dose donor lymphocyte infusions following non-myeloablative allogeneic transplantation are associated with minimal toxicity with sibling donors but a significant risk of severe GVHD with unrelated donors [abstract]. Blood. 2001;98:672a.
18. McSweeney PA, Storb R. Mixed chimerism: Preclinical studies and clinical applications. Biol Blood Marrow Transplant. 1999;5:192-203.